Annexon Biosciences
CA - Brisbane
BiotechnologyFocus: Neurodegenerative and autoimmune disorders
Annexon Biosciences is a life sciences company focused on Neurodegenerative and autoimmune disorders.
ImmunologyNeurology
Funding Stage
PUBLIC
Open Jobs
3
Pipeline & Clinical Trials
Evaluating the Relationship Between Function and Structure in ARCHER II-like Population Using Data F
Age Related Macular Degeneration (AMD)Clinical Trials (1)
NCT07424235Evaluating the Relationship Between Function and Structure in ARCHER II-like Population Using Data From a Natural History Cohort
N/APhase 1
Clinical Trials (1)
NCT04535752A Single and Multiple Ascending Dose Study of ANX009 in Normal Healthy Volunteers (NHV)
Phase 1ANX105
HealthyClinical Trials (1)
NCT05288881Single Ascending Dose Study of ANX105
Phase 1Phase 1
Clinical Trials (1)
NCT03010046Single Dose Study of ANX005 in Healthy Volunteers
Phase 1ANX005
Guillain-Barré SyndromeClinical Trials (1)
NCT04035135A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)
Phase 1ANX1502
HealthyClinical Trials (1)
NCT05521269Dose Study of ANX1502 in Healthy Volunteers
Phase 1ANX009
Lupus NephritisClinical Trials (1)
NCT05780515A Study of ANX009 in Adult Participants With Lupus Nephritis
Phase 12.5mg ANX007
Open Angle GlaucomaClinical Trials (1)
NCT04188015Study of ANX007 in Participants With Primary Open-angle Glaucoma
Phase 1ANX007
Open-angle GlaucomaClinical Trials (1)
NCT03488550Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma
Phase 1Phase 2
Clinical Trials (1)
NCT04691570Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)
Phase 2ANX007
Geographic AtrophyClinical Trials (1)
NCT04656561A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy
Phase 2Phase 2
Clinical Trials (1)
NCT04569435Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)
Phase 2ANX005
Huntington DiseaseClinical Trials (1)
NCT04514367An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease
Phase 2Tanruprubart
Guillain-Barre SyndromeClinical Trials (1)
NCT07020819An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
Phase 3ANX005
Guillain-Barre SyndromeClinical Trials (1)
NCT04701164Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome
Phase 3Vonaprument
Geographic AtrophyClinical Trials (1)
NCT06510816A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Geographic Atrophy (GA)
Phase 3Open Jobs (3)
Vice President, Market Access
San Francisco Bay Area
Commercial4d ago
$312K - $350K/yr
Vice President, Drug Safety and Pharmacovigilance
San Francisco Bay Area
626 - Drug Safety & Pharmacovigilance1mo ago
Senior Director, Clinical Development
San Francisco Bay Area
Clinical Development1mo ago
$336K - $374K/yr
Interview Prep Quick Facts
Portfolio: 16 clinical trials
Open Roles: 3 active jobs
Hiring Trend
Stable
3
Open Roles
+1
Added
-0
Filled/Removed
Based on last 4 crawl cycles